943 related articles for article (PubMed ID: 23665737)
1. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
2. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
3. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
4. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
5. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
[TBL] [Abstract][Full Text] [Related]
6. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
7. Accelerated approval of oncology products: a decade of experience.
Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes supporting anticancer product approvals.
Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
[TBL] [Abstract][Full Text] [Related]
9. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
10. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
McKee AE; Farrell AT; Pazdur R; Woodcock J
Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
12. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
13. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
14. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
15. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
Liu ITT; Kesselheim AS; Cliff ERS
JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
[TBL] [Abstract][Full Text] [Related]
16. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
17. End points and United States Food and Drug Administration approval of oncology drugs.
Johnson JR; Williams G; Pazdur R
J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
[TBL] [Abstract][Full Text] [Related]
18. 2011 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
[No Abstract] [Full Text] [Related]
19. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
Ribeiro TB; Buss L; Wayant C; Nobre MRC
PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
[TBL] [Abstract][Full Text] [Related]
20. Meaningful endpoints for therapies approved for hematologic malignancies.
Smith BD; DeZern AE; Bastian AW; Durie BGM
Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
